In this episode of the Huberman Lab, Dr. Matthew Johnson explores the science of psychedelic compounds and their effects on perception, emotion, and cognition. He explains how substances like LSD, psilocybin, and MDMA interact with the brain's serotonin system and how various factors—including dosage and environment—influence the psychedelic experience.
The discussion covers both the fundamentals of how psychedelics work in the brain and their potential therapeutic applications. Johnson shares insights from clinical trials at Johns Hopkins that investigate psychedelic therapy for conditions such as smoking cessation and end-of-life distress. He also discusses ongoing research into using psychedelics to treat brain injuries and enhance cognitive function in retired athletes who have experienced repetitive head impacts.
Sign up for Shortform to access the whole episode summary along with additional materials like counterarguments and context.
In a discussion between Andrew Huberman and Matthew Johnson, they explore the nature of psychedelics - substances that profoundly alter perception, emotion, and cognition. These compounds, including LSD, psilocybin, DMT, mescaline, [restricted term], and MDMA, primarily work by targeting the brain's serotonin system, specifically the serotonin 2A receptor.
Johnson explains that psychedelic experiences can range from profound to extremely challenging, with substances like LSD and psilocybin more likely to induce "bad trips" compared to MDMA. In controlled settings, about one-third of participants may experience a challenging trip with high doses of psilocybin. The nature of these experiences largely depends on the specific compound, dosage, and environmental factors.
According to Johnson, psychedelics can disrupt our brain's typical top-down processing approach, leading to a dissolution of existing mental models. This disruption can result in significant re-evaluations of how we relate to the world and ourselves. The substances can temporarily reduce identity rigidity, expanding one's sense of possibility and agency. Even challenging experiences can lead to transcendental insights if the individual can surrender to the experience.
Johnson discusses promising clinical trials at Johns Hopkins using psychedelic therapy for various conditions, including smoking cessation and end-of-life distress. The therapy involves careful preparation, a supportive environment, and integration of insights. Participants often report lasting positive changes in their thought patterns and behaviors.
Regarding neurological conditions, preliminary research suggests potential benefits for brain injury and stroke recovery. Johnson plans to conduct studies with retired athletes who have experienced repetitive head impacts, using advanced imaging to investigate whether psychedelics can treat associated depression and enhance cognitive functions.
1-Page Summary
The discussion between Andrew Huberman and Matthew Johnson explores the categorization of psychedelics, their effects on the mind, and the variables influencing experiences during their use.
Psychedelics are a class of substances with the power to profoundly alter perception, emotion, and cognition. The term includes a variety of compounds such as LSD, psilocybin, DMT, mescaline, [restricted term], and MDMA. These substances, particularly LSD and psilocybin, target the serotonin system in the brain.
Discussion highlights that classic psychedelics primarily function as agonists or partial agonists at the serotonin 2A receptor. This action is what influences the altered states of mind associated with these substances, such as shifts in perception and emotional well-being, along with changes in cognition.
The experiences elicited by psychedelics can range from profound to extremely unsettling, with the potential for both enlightening and frightening "bad trips."
Johnson points out the unpredictability of psychedelic experiences, cautioning that participants in research trials might encounter the most beautiful or the most terrifying moments of their lives. He mentions that with MDMA, the likelihood of a challenging experience is much lower than with substances like LSD or psilocybin.
Defining and Classifying Psychedelics
Exploring how substances like LSD and psilocybin affect our mental processes, researchers delve into the complex interaction between psychedelics and the serotonin system.
Matthew Johnson discusses how our brains serve as prediction machines using a top-down processing approach, which psychedelics can disrupt, leading to a dissolution of preexisting mental models and boosting perceptual awareness and flexibility.
Psychedelics, due to their interaction with the serotonin system, are implicated in challenging the models we have of the world and ourselves. This disruption can result in significant re-evaluations of our relationship with the world around us, altering perceptions and leading individuals to experience common elements of life, like the human hand, with intense interest and a sense of rediscovery.
Johnson talks about the changes in self-representation that commonly occur after a psychedelic experience. He suggests that the largest model affected by psychedelics is the self, defined by personal traits or challenges. Psychedelics can temporarily reduce the rigidity of one's identity, allowing a person to think they are capable of doing things they'd normally consider impo ...
Mechanisms By Which Psychedelics Alter Perception and Self-Representation
Recent conversations with experts like Matthew Johnson and Andrew Huberman have shed light on the promising effects of psychedelic therapy for various mental health conditions and the potential neurological benefits that warrant further investigation.
Johnson discusses how psychedelic therapy has been applied in clinical trials at Johns Hopkins, targeting conditions such as smoking cessation and end-of-life distress among cancer patients.
In studies, participants experience a profound shift in agency and self-identity after a psychedelic experience, which enables them to escape negative self-modeling, such as the notion that they cannot quit an addiction or must resign to suffering. Participants consistently report a newfound ability to choose healthier behaviors and thought patterns. These changes are attributed to the psychedelic experience, which appears to enable a reprocessing of trauma with lasting effects, akin to memory reconsolidation.
Preparation for psychedelic therapy involves establishing a therapeutic rapport and informing participants about the variability of psychedelic experiences. Johnson emphasizes that the environment plays a significant role; creating a "container" where patients learn to relinquish control and build trust with the therapist is crucial. The therapist helps navigate the psychedelic experience, providing reassurance and safety protocols, such as administering [restricted term] under the tongue to lower blood pressure if necessary. Johnson further shows interest in high doses of psychedelics for treating depression, suggesting that such doses could have lasting benefits.
Huberman and Johnson discuss the frontiers of psychedelic research, particularly its potential in treating neurological injuries and disorders.
Anecdotes an ...
Therapeutic Applications of Psychedelics
Download the Shortform Chrome extension for your browser